Cargando…
Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy
Many women experience bothersome vasomotor and vaginal symptoms during the menopausal transition. Decreasing levels of estrogens during menopause are also associated with reduced bone density and an increased risk of osteoporosis. Combined estrogen/progestin therapy (hormone therapy) effectively tre...
Autores principales: | Komm, Barry S, Mirkin, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325004/ https://www.ncbi.nlm.nih.gov/pubmed/22505832 http://dx.doi.org/10.2147/IJWH.S29346 |
Ejemplares similares
-
Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination
por: Mirkin, Sebastian, et al.
Publicado: (2013) -
Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene
por: Kagan, Risa, et al.
Publicado: (2016) -
The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause
por: Lello, Stefano, et al.
Publicado: (2017) -
The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy
por: Komm, Barry S., et al.
Publicado: (2012) -
Conjugated Estrogens and Bazedoxifene Improve β Cell Function in Obese Menopausal Women
por: Lovre, Dragana, et al.
Publicado: (2019)